36.26 +0.25 (0.69%)
After hours: 4:49PM EST
|Bid||34.01 x 500|
|Ask||34.02 x 800|
|Day's Range||35.88 - 36.49|
|52 Week Range||31.67 - 39.43|
|PE Ratio (TTM)||10.23|
|Forward Dividend & Yield||1.36 (3.75%)|
|1y Target Est||N/A|
Novartis: What Are the Major Growth Drivers for 2018? On October 31, 2017, Novartis (NVS) announced the submission of a supplemental biologics license application (or sBLA) to the FDA. The sBLA seeks approval for Kymriah as a treatment option for adult patients with relapsed/refractory diffuse large B-cell lymphoma (or r/r DLBCL).
As the battle to buy Pfizer’s $20 billion consumer business heats up, Lysol-owner Reckitt Benckiser is trying to convince investors that its acquisition record is clean.
GlaxoSmithKline’s (GSK) Pharmaceuticals business includes respiratory products, immuno-inflammation products, HIV products, and its established products portfolio. The chart below illustrates the revenues for its Pharmaceuticals business since 1Q16. The Pharmaceuticals segment reported revenues of ~4.5 billion pounds in 4Q17, driven by the increase in sales of its HIV products (Triumeq and Tivicay). It was also driven by growth in the sales of its new respiratory products (Ellipta portfolio and Nucala).
Vasant Narasimhan, the 41-year-old chief executive at Novartis AG, is vowing data science and digital technologies will revolutionize the company’s drug-development pipeline.
If there were a healthcare Olympics, this company would bring home the gold this year for its dividend-friendly performance.
Pfizer Inc (NYSE:PFE) outperformed the Pharmaceuticals industry on the basis of its ROE – producing a higher 34.94% relative to the peer average of 10.62% over the past 12 months.Read More...
Alberta Investment Management Corp. invests on behalf of 26 provincial pension, endowment and government funds, but that might not be obvious to an observer based on the pension manager’s fourth-quarter trades. Aimco, as the entity is known, made some drastic changes in the overall portfolio, trades that we’d expect to see in an aggressively managed fund on the hunt for growth, not in what we’d assume should be an approach as focused on protection as incremental upside. Perhaps the funds Aimco manages are incentivized to find big, immediate returns.
What Led to Stellar Rise of AMAG Pharmaceuticals in February? AMAG Pharmaceuticals (AMAG) is a biopharmaceutical company with a focus on clinical research and the development of therapeutics. AMAG also provides services for preserving umbilical cord stem cells and cord tissue units through cord blood registry.
Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.
According to the terms of the agreement, Sangamo Therapeutics will receive an upfront payment of $12 million from Pfizer. Sangamo, using its ZFP-TF platform, will develop ZFP-TF candidates, while Pfizer will undertake operational and financial responsibilities for the further research and development, manufacturing, and commercialization of the ZFP-TF program.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. PFE credit default swap spreads are within the middle of their range for the last three years.
FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.